Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...
Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...
Clinical Trials Arena on MSN
J&J’s Imaavy posts win in Phase II SLE trial
Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback